Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide

Journal of the American Veterinary Medical Association

Volumn 233, Issue 8, 2008, Pages 1270-1277

  Kluger, Elissa K ^a   Malik, Richard ^a   Ilkin, William J ^b   Snow, David ^c   Sullivan, David R ^d   Govendir, Merran ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Kirrawee Veterinary Hospital   (Australia)

^c Symbion Vetnostics   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BROMIDE; PHENOBARBITAL; POTASSIUM BROMIDE; POTASSIUM DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DOG; DOG DISEASE; EPILEPSY; FEMALE; HYPERTRIGLYCERIDEMIA; MALE; PANCREATITIS; RISK FACTOR;

ANIMALS; BROMIDES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOG DISEASES; DOGS; EPILEPSY; FASTING; FEMALE; HYPERTRIGLYCERIDEMIA; MALE; PANCREATITIS; PHENOBARBITAL; POTASSIUM COMPOUNDS; RISK FACTORS; TRIGLYCERIDES;

ANIMALIA; CANIS FAMILIARIS;

EID: 55349092011     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.233.8.1270     Document Type: Article

References (26)

1. Govendir M, Perkins M, Malik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 2005;83:602-608.
2. Foster SF, Church DB, Watson ADJ. Effects of phenobarbitone on serum biochemical tests in dogs. Aust Vet J 2000;78:23-26.
3. Gaskill CL, Cribb AE. Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vet J 2000;41:555-558.
4. Rogers WA, Donovan EF, Kociba GJ. Idiopathic hyperlipoproteinemia in dogs. J Am Vet Med Assoc 1975;166:1087-1091.
5. Aarli JA. Neurological manifestations in hyperlipidemia. Neurology 1968;18:883-886.
6. Bodkin K. Seizures associated with hyperlipoproteinemia in a Miniature Schnauzer. Canine Pract 1992;17(1):11-15.
7. Whitney MS. Evaluation of hyperlipidemias in dogs and cats. Semin Vet Med Surg (Small Anim) 1992;7:292-300.
8. Mead JR, Irvine SA, Ramjii DP. Lipoprotein lipase: structure, function, regulation and role in disease. J Mol Med 2002;80:753-769.
9. Fugier C, Tousaint J-J, Prieur X, et al. The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone. J Biol Chem 2006;281:11553-11559.
10. Goldberg DM, Roomi MW, Yu A, et al. Effects of phenobarbital upon triacylglycerol metabolism in the rabbit. Biochem J 1980;192:165-175.
11. Goldberg DM, Yu A, Roomi MW, et al. Effects of phenobarbital upon triacylglycerol metabolism in the guinea pig. Can J Biochem 1981;59:48-53.
12. Heller FR, Desager JP, Harvengt C. Changes in plasma activities of lipolytic enzymes and lipids of normohpidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate. Int J Clin Pharmacol Ther Toxicol 1988;26:138-142.
13. LaFlamme D. Development and validation of a body condition score system for dogs; a clinical tool. Canine Pract 1997;22(4):10-15.
14. McNeely S, Seatter K. The 16-hour-standing test and lipoprotein electrophoresis compared for detection of chylomicrons in plasma. Clin Chem 1981;27:731-732.
15. Sattler W, Mohr D, Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by high performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol 1994;233:469-489.
16. Lairon D, Lopez-Miranda J, Williams C. Methodology for studying postprandial lipid metabolism. Eur J Clin Nutr 2007; 61:1145-1161.
17. Jeusette IC, Lhoest ET, Istasse LP, et al. Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. Am J Vet Res 2005;66:81-86.
18. Podell M. Seizures in dogs. Vet Clin North Am Small Anim Pract 1996;26:779-809.
19. Ruotolo G, Howard By Robbins DC. Dyslipidemia of obesity. Available at: endotext.com/obesity/obesity10/obesityframe10. htm. Accessed Aug 20, 2006.
20. Eiris JM, Lojo S, Del Rio MC, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155-1157.
21. Watson TD, Mackenzie JA, Stewart JP, et al. Use of oral and intravenous fat tolerance tests to assess plasma chylomicron clearance in dogs. Res Vet Sci 1995;58:256-262.
22. Acheson DWK, Rose P, Houston JB, et al. Induction of cytochromes P-450 in pancreatic disease: consequence, coincidence or cause? Clin Chim Acta 1985;153:73-84.
23. Bauer JE. Lipoprotein-mediated transport of dietary and synthesized lipids and lipid abnormalities of dogs and cats. J Am Vet Med Assoc 2004;224:668-675.
24. Johnson MC. Hyperlipidemia disorders in dogs. Compend Contin Educ Pract Vet 2005;27:361-370.
25. Gaskill CL, Burton SA, Gelens HCJ, et al. Effects of phenobarbital treatment on serum thyroxine and thyroid-stimulating hormone concentrations in epileptic dogs. J Am Vet Med Assoc 1999;215:489-496.
26. Gaskill CL, Hoffmann WE, Cribb AE. Serum alkaline phosphatase isoenzyme profiles in phenobarbital-treated epileptic dogs. Vet Clin Pathol 2004;33:215-222.